

- demographic study of mortality. *Fd. Chem. Toxicol.*, **22**, 39, 1984.
- (5) World Health Organization: *Environmental Health Criteria II. Mycotoxins* (Published under the sponsorship of UNEP, ILO and WHO). Geneva, 1979. p. 41.
- (6) Sieber S.M., Correa P., Dalgaard D.W., Adamson R.H. Induction of osteogenic sarcomas and tumors of hepatobiliary system in non-human primates with aflatoxin B<sub>1</sub>. *Cancer Res.*, **39**, 4545, 1979.
- (7) Dickens F., Jones H.E.H., Waynforth H.B. Oral, subcutaneous, and intratracheal administration of carcinogenic lactones and related substances: the intratracheal administration of cigarette tar in the rat. *Br. J. Cancer*, **20**, 134, 1966.
- (8) Peers F.G., Linsell C.A. Dietary aflatoxin and liver cancer - a population based study in Kenya. *Br. J. Cancer*, **27**, 473, 1973.
- (9) Peers F.G., Gilman G.A., Linsell C.A. Dietary aflatoxins and human liver cancer - a study in Swaziland. *Int. J. Cancer*, **17**, 167, 1976.
- (10) Shank R.C., Bhamarapravati N., Wogan G.N. Dietary aflatoxin and human liver cancer. IV. Incidence of primary liver cancer in two municipal populations of Thailand. *Fd. Cosmet. Toxicol.*, **10**, 171, 1972.
- (11) Alpert M.E., Hutt M.S.R., Wogan G.N., Davidson C.S. The association between aflatoxin content of food and hepatoma frequency in Uganda. *Cancer*, **28**, 253, 1971.
- (12) Oettle A.G. Cancer in Africa especially in regions South of Sahara. *J. Nat. Cancer Inst.*, **33**, 383, 1964.
- (13) Dvorackova I., Stora C., Ayraud N. Evidence for aflatoxin B<sub>1</sub> in two cases of lung cancer in man. *J. Canc. Res. Clin. Oncol.*, **100**, 221, 1981.
- (14) Deger G.E. Aflatoxin - human colon carcinogenesis. *Ann Intern. Med.*, **85**, 204, 1976.
- (15) Baxter C.S., Wey H.E., Burg W.R. A prospective analysis of the potential risk associated with inhalation of aflatoxin contaminated grain dusts. *Fd. Cosmet. Toxicol.*, **19**, 765, 1981.
- (16) Wogan G.N. Naturally occurring carcinogens in foods. *Prog. Exp. Tumor Res.*, **11**, 134, 1969.
- (17) Burzynski S.R. Purified antineoplaston fractions and methods of treating neoplastic disease. U.S. Patent Nos. 4,470,970, 4,458,057, 4,459,325; Can. 1188218; Span. 512,894; S. Africa 824178; Israel 65960; Austral. 551109; European 0,069232.
- (18) Burzynski S.R., Hendry L.B., Mohabbat M.O., Liao M.C., Khalid M., Burzynski B. Structure determination, synthesis and animal toxicity studies of Antineoplaston A10. *Proc. 13th Int. Cong. Chemother.* Vienna, Austria, 1983, Vol. 17, PS 12.4, 11-4.
- (19) James M.O., Smith R.L., Williams F.R.S., Reidenberg M. The deconjugation of phenylacetic acid in man, subhuman primates, and some nonprimate species. *Proc. R. Soc. London, B.*, **182**, 25, 1972.
- (20) Kampalath B.N., Liao M.C., Burzynski B., Burzynski S.R. Chemoprevention by Antineoplaston A10 of benzo(a)pyrene induced pulmonary neoplasia. *Drugs Exptl. Clin. Res.*, **XIII** (Suppl. 1), 51, 1987.
- (21) Eriguchi N., Hara H., Yoshida H., Nishida H., Nakayama T., Ohishi K., Tsuda H., Inoue S., Ikeda I. Chemopreventive effect of Antineoplaston A10 on urethan-induced pulmonary neoplasia in mice. *J. Jpn. Soc. Cancer Ther.*, **23**(7), 1560, 1988.
- (22) Muldoon T.G., Copland J.A., Lehner A.F., Hendry L.B. Inhibition of mouse spontaneous mammary tumor development by Antineoplaston A10. *Drugs Exptl. Clin. Res.*, **XIII** (Suppl. 1), 83, 1987.
- (23) Burzynski S.R., Mohabbat M.O., Burzynski B. Human toxicology studies on oral formulation of Antineoplaston A10. *Drugs Exptl. Clin. Res.*, **XII**, 891, 1984.
- (24) Wogan G.N. Aflatoxin carcinogenesis. In: H. Bush, ed. "Methods of cancer research". Vol. 7, Academic Press, New York, 1973, p. 309.
- (25) Williams G.M., Tanaka T., Maeura Y. Dose related inhibition of aflatoxin B<sub>1</sub> induced hepatocarcinogenesis by the phenolic antioxidants, butylated hydroxyanisole and butylated hydroxytoluene. *Carcinogenesis*, **7**, 104, 1986.
- (26) Muldoon T.C., Copland J.A., Hendry L.B. Actions of Antineoplaston A10 on the genesis and maintenance of specific subpopulations of rodent mammary tumor cells. *Adv. Exp. Clin. Chemother.*, in press.
- (27) Busby W.F., Paliialunga S., Newberne P.M., Wogan G.M. Transfer RNA methylene activity and capacity during aflatoxin B<sub>1</sub> induced hepatocellular carcinogenesis. *Cancer Res.*, **36**, 213, 1976.
- (28) Newberne P.M., Wogan G.N. Sequential morphologic changes in aflatoxin B<sub>1</sub> carcinogenesis in rat. *Cancer Res.*, **28**, 770, 1968.
- (29) Albanes, D. Total calories, body weight and tumor incidence in mice. *Cancer Res.*, **47**, 1987, 1987.
- (30) Stewart H.L., Williams G.M., Keyser C.H., Lombard L.S., Montali R.J. Histologic typing of liver tumors of rat. *J. Natl. Cancer Inst.*, **64**, 177, 1980.
- (31) Iverson F., Cambell J., Clayson D., Hierlihy S., Labossiere E., Hayward S. Effects of antioxidants on aflatoxin induced hepatic tumors in rats. *Cancer Lett*, **34**, 139, 1987.
- (32) McLean A.E.M., Marshall A. Reduced carcinogenic effects of aflatoxin in rats given phenobarbitone. *Br. J. Exp. Path.*, **52**, 322, 1971.
- (33) Novi A.M. Regression of aflatoxin B<sub>1</sub> induced hepatocellular carcinomas by reduced glutathione. *Science*, **212**, 541, 1981.
- (34) Burzynski S.R., Mohabbat M.O., Burzynski B. Animal toxicology studies on oral formulation of Antineoplaston A10. *Drugs Exptl. Clin. Res.*, **X**, 113, 1984.
- (35) Hendry L.B., Lehner A.F., Burzynski S.R. Spectroscopic studies of the interaction of Antineoplaston A10 with DNA. 12th Symp. Int. Assoc. Compar. Res. Leuk. Rel. Dis., Hamburg, Germany, 1985.